The development of Gal-3 inhibitors as therapeutic agents is both innovative and promising; however, further clinical research is required to comprehensively evaluate their potential in the prevention and management of cardio–renal–metabolic diseases. This evidence concerns the gene LGALS3 and Other metabolic disease.